SNTG2-AS1

Across TCGA pan-cancer cohorts, SNTG2-AS1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SNTG2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where SNTG2-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types SNTG2-AS1 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

UCEC, KIRC, and BRCA are the cancer types where SNTG2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNTG2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	−1.486	<.001	8	view →
KIRC	All	All	+0.596	.001	7	view →
BRCA	All	III,IV	−1.082	<.001	6	view →
BLCA	Female	All	−0.662	<.001	6	view →
KIRP	All	III,IV	+1.276	.007	5	view →
STAD	All	II,III,IV	−0.413	<.001	5	view →
LUAD	Male	All	−0.256	.006	3	view →
PRAD	All	All	+1.075	<.001	2	view →
KICH	All	All	−0.684	.004	2	view →
THCA	Male	III,IV	−0.462	<.001	2	view →
COAD	Female	All	−0.285	<.001	2	view →
ESCA	Female	All	−0.366	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SNTG2-AS1–UCEC

Open the UCEC breakdown →